Adroit Market Research - Industry Insights

Despite shrinking number of cancer fatality in the recent decade owing to advances in early detection and diagnostics, cancer incidences are far from depreciation. According to a recent statistical report by Canadian Cancer Society, an approximate number of 220,400 cases of cancer are expected to be registered in Canada alone in 2019, besides death toll rising to over 82,100 accounting for over 30% fatality in Canada.

Additionally, besides burgeoning cancer occurrences across developed economies, Cancer is a baffling condition in emerging countries as well such as China. A

Despite shrinking number of cancer fatality in the recent decade owing to advances in early detection and diagnostics, cancer incidences are far from depreciation. According to a recent statistical report by Canadian Cancer Society, an approximate number of 220,400 cases of cancer are expected to be registered in Canada alone in 2019, besides death toll rising to over 82,100 accounting for over 30% fatality in Canada.

Additionally, besides burgeoning cancer occurrences across developed economies, Cancer is a baffling condition in emerging countries as well such as China. According to a recent report, in 2018 alone, China witnessed over 2.9 million cancer fatal cases . Despite low occurrence rates in contrast to the USA and UK, China faces higher fatality as compared to these regions, opines the report. Such rapidly scaling instances of cancer and cancer associated deaths have long enabled massive reliance on appropriate diagnostics and therapeutics. A recent report opines that cancer fatality in the US has tangibly fallen, triggered by a host of factors, wherein early detection and therapeutics is prime.  

Favorable Funding Assistance to Leverage Relentless Strides in Cancer Diagnostics

On the back of optimistic adoption of cancer diagnostics, followed by growing incidences, favorable technological advances, and fast improving healthcare infrastructure, cancer diagnostics market is likely to remain primarily rewarding in the forthcoming years. Besides aforementioned growth propellants, cancer diagnostics market is likely to remain lucrative, on the back of favorable funding assistance, both public and private.

In this regard, India based Onco.com which is a digital cancer funding institution has recently affirmed its latest fund collection worth, $7million. The organization is looking forward to judiciously leverage the funds towards meeting most needs of cancer patients as well as their kith and kin. It is dedicated to offering scientific guidance aligning with personalized treatment to cancer patient pools, on the back of its extensive team of oncologists. The institution is a complete solution provider to deliver complete assistance besides flawless care delivery. These concurrent developments are likely to keep growth pace steady in the coming years in cancer diagnostics market.  

Further, according to new initiatives towards cancer diagnostics and therapeutics, The Senate Labor, Health and Human Services and Education Subcommittee suggested $3 billion funds towards healthcare, and more particularly dedicating a funding spike, worth $5, million under the realm of Centers for Disease Control and Prevention. These developments further expedite R&D excavations and concomitant growth in cancer diagnostics market.

New Imaging technology to Pioneer Accurate Cancer Detection for Promising Therapeutics

Next generation medical imaging technologies are likely to steer ample growth prospects in cancer diagnostics space. These developments are likely to culminate in thorough diagnostics and cancer therapeutics. Several top notch medical institutions are investing resources towards unravelling new breakthrough technologies in medical imaging techniques that can effectively diagnose and also treat diverse forms of cancers. In one of the recent developments, Heriot-Watt University is claiming to have successfully devised an imaging technology that produces accurate medical images within couple at higher resolution, in contrast to conventional imaging technologies. The precision level scales up to 0.04mm.

This new imaging technology based on super-resolution features is touted to push success ratios of cancer identification and adequate testing and clinical trials are underway to affirm efficacy.

New Market Disruptors Invest in Multi Cancer Detection for Disease Management

The development is therefore anticipated to push cancer diagnostics to new heights, besides elaborating therapeutics scope amongst patients. Thus cancer occurrences and subsequent fatality are likely to be significantly arrested in forthcoming years.

Yet another significant university development concerning cancer diagnostics has unfurled at University of Queensland who have identified a novel DNA structure mostly prevalent across commonly occurring cancer types such as prostate and breast cancers. The technology is based on gold substrate which accentuates detection and visibility, allowing superlative medical imaging results. The development is a new one and is likely to further expedite cancer diagnostics and therapeutics in the coming years. A path breaking liquid biopsy test that aids in multiple cancer detection is doing the rounds, under the name, CancerSEEK, developed and commercialized by a new market player, Thrive Earlier Detection Corp to aid in early cancer detection for effective cancer therapeutics.

This novel development is anticipated to help in multiple cancer detection thereby expediting scope in accurate disease management and healing. Striving to maneuver substantial progress in minimally invasive cancer diagnostics, scientists from University of Alberta have pioneered a new technology to diagnose and subsequently improve human papillomavirus (HPV) based cancer occurrences, thus diversifying scope of cancer diagnostics manifold. This technology is thoroughly non-invasive and disintegrates water droplets in oil, followed by subsequent testing to identify proteins, DNA and RNA components for accurate cancer detection. This development is yet another significant milestone in cancer diagnostics market.

Cancer diagnostics and preventive screening is gaining tangible leaps ahead in present times as opposed to traditional therapeutics. Therefore, on the back of rapid health awareness and parallel healthcare expenditure, emerging economies are also putting in their best foot forward in harnessing cancer diagnosis in a bid to limit occurrences and fatality. Such novelties in early detection are poised to further expedite growth opportunities in cancer diagnostics market.